(PharmaNewsWire.Com, July 12, 2017 ) The bladder is a hollow organ in the lower part of the abdomen that stores urine until it is passed out of the body.
The most common type of bladder cancer is transitional cell carcinoma, which begins in urothelial cells that line the inside of the bladder. Urothelial cells are transitional cells, which are able to change shape and stretch when the bladder is full. This type of cancer is also called urothelial carcinoma. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells lining the bladder) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids).
People who smoke have an increased risk of bladder cancer. Being exposed to certain chemicals and having chronic bladder infections can also increase the risk of bladder cancer. The most common sign of bladder cancer is blood in the urine. Bladder cancer is often diagnosed at an early stage, when the cancer is easier to treat.
The report also presents detailed analysis of multitude of factors affecting the Bladder Cancer Therapeutics market bearing either positive or negative outcomes. Some of those factors are:
• Rising healthcare expenditure
• Increasing cancer patient population
• Growing involvement of universities & research institutes
• Rising focus of foreign pharmaceutical companies on Asian market
• Unawareness among bladder cancer patients about advanced cancer therapies
• Presence of more number of generic bladder cancer therapeutics
For granular level understanding the Bladder Cancer Therapeutics Market is segmented based on product and application, each being provided with Market Size Estimates and Y-o-Y Forecasts. Asia-Pacific Bladder Cancer Therapeutics market is segmented based on type and treatment. Based on type, the market is further sub-segmented as Transitional Cell Bladder Cancer, Non Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder, and Rare Bladder Cancers. Based on treatment, the market is further segmented as Surgery, Chemotherapy, Immunotherapy, Radiation Therapy, and Intravesical Therapy.
The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. The Asia-Pacific region is projected to grow at the highest CAGR during the forecast period due to reasons such as rising aging population and increasing participation of several private & public establishments to organize awareness programs on Bladder Cancer.
The key players in Bladder Cancer Therapeutics market include, Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Celgene Corporation (U.S.).
Checkout other related studies in the Pharmaceuticals Segment:
The Asia-Pacific Bladder Cancer Therapeutics Market report offers wide-range of scope:
• Regional and country-level analysis that provides an individual perspective of Asia-Pacific region and the aforementioned countries
• Know more about key areas of industry growth via detailed Segment-level analysis on basis of product type long with market size forecasts and y-o-y estimations
• Detailed explanation of major drivers, restraints, opportunities, and challenges(DROC) that affect the market and impact the ever-shifting market dynamics
• Strategic Analyses containing PESTLE and Porter’s Five Forces Analyses which are obtained by studying the macro & micro environmental factors that affect the market demographics
• Comprehensive listing of key market players along with Company overview, product portfolios, financials (subjected to availability), SWOT analysis and analyst overview
• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
• Market Outlook - Investment opportunities devised by stand in experts to provide both individuals and organizations a strong financial foothold in the market
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
